<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugSwotsOutput xmlns:ns2="local"><SWOTs><SWOT><Class>Pituitary disorders</Class><Strengths><Strength name="Strength" sortOrder="1">&lt;para&gt;Gold-standard and most prescribed somatostatin analog, being the most widely studied (in over 600 clinical trials) and with approximately 30 years clinical experience [&lt;ulink linkType="Reference" linkID="1225518"&gt;1225518&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225517"&gt;1225517&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="10">&lt;para&gt;Available in a convenient kit which includes a safety needle, new diluent, vial adaptor and smaller needle gauge [&lt;ulink linkType="Reference" linkID="1388709"&gt;1388709&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225517"&gt;1225517&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="2">&lt;para&gt;Effective in treating acromegaly, achieving growth hormone (GH) levels of &amp;lt; 2.5 ng/ml and normalization of IGF-1 levels in 68% of patients, with 75% of patients exhibiting significant tumor shrinkage [&lt;ulink linkType="Reference" linkID="1225524"&gt;1225524&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225485"&gt;1225485&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225490"&gt;1225490&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225498"&gt;1225498&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="3">&lt;para&gt;Delivers significant improvements in the five common symptoms of acromegaly; parasthesias (46% of patients show symptom control), headache (43%), perspiration (35%), joint pains (29%) and fatigue (24%) [&lt;ulink linkType="Reference" linkID="1225490"&gt;1225490&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225504"&gt;1225504&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="4">&lt;para&gt;Improves or normalizes mortality rates in acromegaly patients with post-treatment GH levels &amp;lt; 2.5 ng/ml [&lt;ulink linkType="Reference" linkID="1225517"&gt;1225517&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225490"&gt;1225490&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="5">&lt;para&gt;Sandostatin LAR was more effective at decreasing GH and IGF-1 levels than &lt;ulink linkType="Drug" linkID="9313"&gt;Somatuline Depot&lt;/ulink&gt; in a head-to-head study in patients with acromegaly [&lt;ulink linkType="Reference" linkID="328007"&gt;328007&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="6">&lt;para&gt;Flexible treatment; available as an &lt;ulink linkType="Drug" linkID="78778"&gt;immediate-release sc injection&lt;/ulink&gt; for administration daily, or as an im dose in three dose strengths administered once every 28 days (Sandostatin LAR Depot) [&lt;ulink linkType="Reference" linkID="1225518"&gt;1225518&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="7">&lt;para&gt;In carcinoid gastroenteropancreatic neuroendocrine tumor (GEP NET) patients, reduced symptoms of diarrhea and flushing frequency by 42 and 84%, respectively; also demonstrated disease stabilization in some patients and suppressed 5-hydroxyindoleacetic acid by up to 50% [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225485"&gt;1225485&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225487"&gt;1225487&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="8">&lt;para&gt;Data from the PROMID trial showed a reduction in risk of disease progression of metastatic NETs of the mid-gut by 66% compared with placebo [&lt;ulink linkType="Reference" linkID="976256"&gt;976256&lt;/ulink&gt;]&lt;/para&gt;</Strength><Strength name="Strength" sortOrder="9">&lt;para&gt;First approved medical treatment for long-term treatment of severe diarrhea associated with metastatic carcinoid or vasoactive intestinal peptide-secreting tumors [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225518"&gt;1225518&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1225485"&gt;1225485&lt;/ulink&gt;]&lt;/para&gt;</Strength></Strengths><Weaknesses><Weakness name="Weakness" sortOrder="1">&lt;para&gt;Lack of patent protection for Sandostatin sc for which generics are available worldwide, following first launch in 2005; formulation patents for Sandostatin LAR also expired in all countries in July 2010, except the US where formulation patents started expiring from 2014 [&lt;ulink linkType="Reference" linkID="1164651"&gt;1164651&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="593323"&gt;593323&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="10">&lt;para&gt;Bradycardia, arrhythmia or conduction abnormalities may occur, with caution required in at-risk patients [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="11">&lt;para&gt;When used with Sandostatin LAR, cyclosporine, beta-blockers and bromocriptine monitoring and potential dose adjustment are required [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="12">&lt;para&gt;Safety and effectiveness in pediatric patients have not been demonstrated [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="13">&lt;para&gt;May alter absorption of dietary fats, and depressed vitamin B12 levels have been reported [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="14">&lt;para&gt;&lt;ulink linkType="Drug" linkID="91112"&gt;Signifor LAR&lt;/ulink&gt; was significantly superior to Sandostatin LAR at providing biochemical control (GH &amp;lt;2.5 microg/l and normal IGF-1) at 12 months for first-line acromegaly treatment in the PASPORT-ACROMEGALY study [&lt;ulink linkType="Reference" linkID="2038530"&gt;2038530&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="2">&lt;para&gt;Only approved for severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, unlike Somatuline Depot which is approved for GEP NETs to improve progression-free survival and for the treatment of carcinoid syndrome where it reduces the frequency of short-acting somatostatin analog rescue therapy [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1153296"&gt;1153296&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="3">&lt;para&gt;Im injection by a healthcare professional required once monthly for Sandostatin LAR, in contrast to Somatuline Depot&amp;apos;s sc delivery device, which is potentially less painful and can be self-administered (outside the US); a 120-mg Somatuline Depot dose can be administered every 6 to 8 weeks for acromegaly; competitor &lt;ulink linkType="Drug" linkID="7590"&gt;Somavert&lt;/ulink&gt; can also be self-administered [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1609324"&gt;1609324&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1153296"&gt;1153296&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1174654"&gt;1174654&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1228456"&gt;1228456&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="4">&lt;para&gt;The immediate-release product requires 2- to 3-times daily dosing [&lt;ulink linkType="Reference" linkID="1301912"&gt;1301912&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="5">&lt;para&gt;The most common adverse reactions in patients with acromegaly are diarrhea, cholelithiasis, abdominal pain and flatulence [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="6">&lt;para&gt;The most common adverse reactions in patients with carcinoid syndrome are back pain, fatigue, headache, abdominal pain, nausea and dizziness [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="7">&lt;para&gt;Use is associated with gallbladder abnormalities [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="8">&lt;para&gt;Risk of hypoglycemia or hyperglycemia, with glucose level monitoring recommended [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;]&lt;/para&gt;</Weakness><Weakness name="Weakness" sortOrder="9">&lt;para&gt;Associated more frequently with hypothyroidism compared with rare occurrences with Somatuline Depot [&lt;ulink linkType="Reference" linkID="1303533"&gt;1303533&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1153296"&gt;1153296&lt;/ulink&gt;]&lt;/para&gt;</Weakness></Weaknesses><Opportunities><Opportunity name="Opportunity" sortOrder="1">&lt;para&gt;Medical need; patients with acromegaly have a 2-fold higher risk of mortality. Approximately 70% of patients have pituitary macroadenomas and the majority of these patients will have persistent disease and require medical therapy after surgery [&lt;ulink linkType="Reference" linkID="1225517"&gt;1225517&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1229032"&gt;1229032&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1229147"&gt;1229147&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1631946"&gt;1631946&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="2">&lt;para&gt;During transsphenoidal surgery, 50% of tumors are not fully resected, and after transsphenoidal surgery, 30 to 45% of patients do not achieve a successful surgical cure and require medical therapy [&lt;ulink linkType="Reference" linkID="1225517"&gt;1225517&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="3">&lt;para&gt;Somatostatin analogs are the standard medical therapy option after surgery or when surgery is not an option; more than 90% of GH-secreting pituitary adenomas express somatostatin receptors 2 and 5 targeted by Sandostatin LAR [&lt;ulink linkType="Reference" linkID="1225517"&gt;1225517&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2038506"&gt;2038506&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="4">&lt;para&gt;Life-long therapy, with long-term biochemical control required to achieve reversal of acromegaly comorbidities [&lt;ulink linkType="Reference" linkID="1229032"&gt;1229032&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1631946"&gt;1631946&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2038510"&gt;2038510&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="5">&lt;para&gt;Leverage use in the first-line, promoting data that suggest Sandostatin LAR reduces GH and IGF-1 levels to a similar or greater extent than when administered after surgery and/or radiotherapy, and reduces tumor size [&lt;ulink linkType="Reference" linkID="1229032"&gt;1229032&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="6">&lt;para&gt;According to &lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt;, there are currently no Sandostatin LAR generics approved in major markets, despite patent expiration [&lt;ulink linkType="Reference" linkID="2004756"&gt;2004756&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="7">&lt;para&gt;Although a rare disease, the incidence of GEP NETs in the US has increased by 6.5-fold from 1973 to 2012 [&lt;ulink linkType="Reference" linkID="2013707"&gt;2013707&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2013706"&gt;2013706&lt;/ulink&gt;] &lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="8">&lt;para&gt;Diarrhea is one of the most common and life-disrupting symptoms of carcinoid syndrome, affecting nearly 80% of patients [&lt;ulink linkType="Reference" linkID="2013705"&gt;2013705&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1868679"&gt;1868679&lt;/ulink&gt;]&lt;/para&gt;</Opportunity><Opportunity name="Opportunity" sortOrder="9">&lt;para&gt;More cost-effective than Somatuline Depot in patients with metastatic gastrointestinal NETs [&lt;ulink linkType="Reference" linkID="2038511"&gt;2038511&lt;/ulink&gt;]&lt;/para&gt;</Opportunity></Opportunities><Threats><Threat name="Threat" sortOrder="1">&lt;para&gt;Generic competition for Sandostatin sc, and generic entry is possible at any time for Sandostatin LAR [&lt;ulink linkType="Reference" linkID="1164651"&gt;1164651&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="593323"&gt;593323&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="649873"&gt;649873&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2004756"&gt;2004756&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="10">&lt;para&gt;In the GEP NET market, surgery and radiotherapy are preferred treatment options; competitor Somatuline Depot is also indicated for NETs, and the mTOR inhibitor &lt;ulink linkType="Drug" linkID="13340"&gt;Afinitor&lt;/ulink&gt; and the multi-kinase inhibitor &lt;ulink linkType="Drug" linkID="12973"&gt;Sutent&lt;/ulink&gt; were more recently approved for advanced pancreatic NET [&lt;ulink linkType="Reference" linkID="1631928"&gt;1631928&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1153296"&gt;1153296&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1189198"&gt;1189198&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1193650"&gt;1193650&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="11">&lt;para&gt;Competition also from &lt;ulink linkType="Drug" linkID="58393"&gt;Lutathera&lt;/ulink&gt;, a first-in-class radiopharmaceutical product approved in the US in January 2018 for the treatment of somatostatin receptor-positive GEP NETs [&lt;ulink linkType="Reference" linkID="2000373"&gt;2000373&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="12">&lt;para&gt;Rare diseases; the prevalence of acromegaly is approximately 2.8 to 13.7 cases per 100,000, and NETs affect an estimated 171,000 individuals in the US [&lt;ulink linkType="Reference" linkID="2038512"&gt;2038512&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2013707"&gt;2013707&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2013706"&gt;2013706&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="13">&lt;para&gt;&lt;b&gt;Last updated on June 22, 2018&lt;/b&gt;&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="2">&lt;para&gt;Tolerability issues may limit sales; not all patients can tolerate the Depot formulation [&lt;ulink linkType="Reference" linkID="1225518"&gt;1225518&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="3">&lt;para&gt;&lt;ulink linkType="Company" linkID="17259"&gt;Ipsen&lt;/ulink&gt;&amp;apos;s Somatuline Depot, with its potentially less painful deep sc administration, longer duration of action of 6 to 8 weeks (120-mg ) and ease of administration, and with its a broader label in GEP NETs [&lt;ulink linkType="Reference" linkID="1153296"&gt;1153296&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1609324"&gt;1609324&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1153296"&gt;1153296&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="4">&lt;para&gt;Novartis&amp;apos;s long-acting release depot formulation of its somatostatin analog pasireotide (Signifor LAR) is approved for acromegaly and showed superior efficacy in acromegaly patients not controlled on first-generation somatostatin analogs compared with continued use of Sandostatin LAR and Somatuline Depot; Signifor LAR was also superior to Sandostatin LAR for first-line acromegaly treatment [&lt;ulink linkType="Reference" linkID="1553002"&gt;1553002&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1621026"&gt;1621026&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1615150"&gt;1615150&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2038530"&gt;2038530&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="5">&lt;para&gt;&lt;ulink linkType="Company" linkID="18767"&gt;Pfizer&lt;/ulink&gt;&amp;apos;s GH receptor antagonist Somavert which is a recommended treatment option for acromegaly [&lt;ulink linkType="Reference" linkID="1228461"&gt;1228461&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1631946"&gt;1631946&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2038510"&gt;2038510&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="6">&lt;para&gt;Surgery, especially, transsphenoidal surgery, remains first-line treatment for acromegaly, and radiotherapy is an option when surgery does not result in cure [&lt;ulink linkType="Reference" linkID="1631935"&gt;1631935&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1631932"&gt;1631932&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1631946"&gt;1631946&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2038510"&gt;2038510&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="7">&lt;para&gt;Other treatment options for acromegaly, such as dopamine agonists, eg bromocriptine and cabergoline, which are available as generics [&lt;ulink linkType="Reference" linkID="1631935"&gt;1631935&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1631946"&gt;1631946&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2038510"&gt;2038510&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="8">&lt;para&gt;Investigational agents include &lt;ulink linkType="Company" linkID="1042653"&gt;Chiasma&lt;/ulink&gt;&amp;apos;s oral capsule formulation of octreotide acetate (&lt;ulink linkType="Drug" linkID="66841"&gt;Mycapssa&lt;/ulink&gt;), which would improve dosing convenience, Novartis&amp;apos;s &lt;ulink linkType="Drug" linkID="54478"&gt;CAM-2029&lt;/ulink&gt;, an sc liquid crystal depot formulation of octreotide acetate, Ipsen&amp;apos;s &lt;ulink linkType="Drug" linkID="105424"&gt;BIM-23B065&lt;/ulink&gt;, a chimeric protein combining dopamine 2 and somatostatin 2 receptor agonist activity, &lt;ulink linkType="Company" linkID="1113544"&gt;Strongbridge Biopharma&lt;/ulink&gt;&amp;apos;s modified-release formulation of the novel multi-receptor targeted somatostatin analog &lt;ulink linkType="Drug" linkID="31030"&gt;veldoreotide&lt;/ulink&gt;, with potentially improved efficacy and safety, and &lt;ulink linkType="Company" linkID="29287"&gt;Antisense Therapeutics&lt;/ulink&gt;&amp;apos; &lt;ulink linkType="Drug" linkID="50120"&gt;atesidorsen&lt;/ulink&gt;, an antisense oligonucleotide designed to inhibit IGF-1 mRNA [&lt;ulink linkType="Reference" linkID="1631200"&gt;1631200&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1956970"&gt;1956970&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1782033"&gt;1782033&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1905764"&gt;1905764&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2015864"&gt;2015864&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1995076"&gt;1995076&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2038506"&gt;2038506&lt;/ulink&gt;]&lt;/para&gt;</Threat><Threat name="Threat" sortOrder="9">&lt;para&gt;Potential competition also from &lt;ulink linkType="Company" linkID="1070584"&gt;Crinetics Pharmaceuticals&lt;/ulink&gt;&amp;apos; &lt;ulink linkType="Drug" linkID="106732"&gt;CRN-00808&lt;/ulink&gt;, a non-peptide somatostatin agonist designed to be taken orally, and &lt;ulink linkType="Company" linkID="1111788"&gt;Dauntless Pharmaceuticals&lt;/ulink&gt;&amp;apos; &lt;ulink linkType="Drug" linkID="98338"&gt;DP-1038&lt;/ulink&gt;, a novel formulation of octreotide acetate for intranasal administration, both of which are in early-stage development [&lt;ulink linkType="Reference" linkID="2014425"&gt;2014425&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2001019"&gt;2001019&lt;/ulink&gt;]&lt;/para&gt;</Threat></Threats></SWOT></SWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugSwotsOutput>